title: Influence of rifampin on tocainide pharmacokinetics in humans.
abstract: The effects of metabolic enzyme induction by rifampin on the pharmacokinetics of tocainide were studied in eight healthy volunteers. In an open, unrandomized fashion, volunteers received tocainide hydrochloride 600 mg orally. Blood samples were obtained immediately before and at various time intervals up to 48 hours after the dose. Urine samples were collected before and at various intervals up to 72 hours after the dose. Serum and urine samples were assayed for tocainide content by high-performance liquid chromatography. After a four-week washout period, volunteers ingested 300 mg of rifampin by mouth every 12 hours. After 10 doses, subjects received a second oral dose of tocainide hydrochloride 600 mg, and blood and urine samples were collected as before. During the sampling period, subjects continued to ingest rifampin 300 mg orally every 12 hours. Significant differences in elimination rate constant (average increase, 0.0545 to 0.0748 hr-1), elimination half-life (average reduction, 13.2 to 9.4 hours), oral clearance, and area under the concentration-time curve (average reduction, 76.8 to 55.0 mg.hr/L) between the control and rifampin treatment phases were observed. Volume of distribution and renal clearance of tocainide were not significantly different after rifampin treatment. Tocainide appears to be susceptible to significant drug-drug interactions mediated by metabolic enzyme induction.
authors.affiliation: University of Michigan College of Pharmacy, Ann Arbor.
authors.forename: T L
authors.initials: TL
authors.lastname: Rice
authors.forename: J H
authors.initials: JH
authors.lastname: Patterson
authors.forename: C
authors.initials: C
authors.lastname: Celestin
authors.forename: J R
authors.initials: JR
authors.lastname: Foster
authors.forename: J R
authors.initials: JR
authors.lastname: Powell
mesh_terms: D000328:Adult; D000889:Anti-Arrhythmia Agents / Q000009:adverse effects / Q000493:pharmacokinetics*; D002851:Chromatography, High Pressure Liquid; D005260:Female; D006801:Humans; D008012:Lidocaine / Q000009:adverse effects / Q000031:analogs & derivatives* / Q000493:pharmacokinetics; D008297:Male; D012293:Rifampin / Q000009:adverse effects / Q000494:pharmacology*; D016677:Tocainide
chemical_list: D000889:Anti-Arrhythmia Agents; D016677:Tocainide; D008012:Lidocaine; D012293:Rifampin